SG11202110646PA - A subunit vaccine for treatment or prevention of a respiratory tract infection - Google Patents
A subunit vaccine for treatment or prevention of a respiratory tract infectionInfo
- Publication number
- SG11202110646PA SG11202110646PA SG11202110646PA SG11202110646PA SG11202110646PA SG 11202110646P A SG11202110646P A SG 11202110646PA SG 11202110646P A SG11202110646P A SG 11202110646PA SG 11202110646P A SG11202110646P A SG 11202110646PA SG 11202110646P A SG11202110646P A SG 11202110646PA
- Authority
- SG
- Singapore
- Prior art keywords
- protein
- seq
- sequence
- hmpv
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175413 | 2019-05-20 | ||
| PCT/EP2020/063973 WO2020234300A1 (en) | 2019-05-20 | 2020-05-19 | A subunit vaccine for treatment or prevention of a respiratory tract infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110646PA true SG11202110646PA (en) | 2021-10-28 |
Family
ID=66685352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110646PA SG11202110646PA (en) | 2019-05-20 | 2020-05-19 | A subunit vaccine for treatment or prevention of a respiratory tract infection |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US12162907B2 (https=) |
| EP (1) | EP3972639A1 (https=) |
| JP (1) | JP2022533318A (https=) |
| KR (1) | KR20220010478A (https=) |
| CN (1) | CN114127101A (https=) |
| AU (1) | AU2020277661A1 (https=) |
| BR (1) | BR112021021637A2 (https=) |
| CA (1) | CA3138064A1 (https=) |
| CL (1) | CL2021002819A1 (https=) |
| CO (1) | CO2021014694A2 (https=) |
| EC (1) | ECSP21079178A (https=) |
| GB (1) | GB2598494B (https=) |
| IL (1) | IL287099A (https=) |
| MX (1) | MX2021013111A (https=) |
| MY (1) | MY208001A (https=) |
| PE (1) | PE20220400A1 (https=) |
| PH (1) | PH12021552736A1 (https=) |
| SA (1) | SA521430813B1 (https=) |
| SG (1) | SG11202110646PA (https=) |
| WO (1) | WO2020234300A1 (https=) |
| ZA (1) | ZA202106883B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8986704B2 (en) | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
| WO2018189372A1 (en) | 2017-04-13 | 2018-10-18 | Valneva Austria Gmbh | Multivalent ospa polypeptides and methods and uses relating thereto |
| PH12021552736A1 (en) | 2019-05-20 | 2022-07-11 | Valneva Se | A subunit vaccine for treatment or prevention of a respiratory tract infection |
| CN115698044A (zh) | 2020-04-09 | 2023-02-03 | 瓦尔尼瓦奥地利有限责任公司 | 用于医学用途的包含三种OspA融合蛋白的组合物 |
| CA3174666A1 (en) | 2020-04-09 | 2021-10-14 | Robert Schlegl | Improved methods of producing a lipidated protein |
| NZ798475A (en) | 2020-10-09 | 2026-03-27 | Univ Texas | Prefusion-stabilized hmpv f proteins |
| JP2023549815A (ja) | 2020-11-13 | 2023-11-29 | アイコサバックス， インコーポレイテッド | メタニューモウイルスのためのタンパク質ベースのナノ粒子ワクチン |
| JP2024522385A (ja) * | 2021-04-09 | 2024-06-19 | ヴァルネヴァ エスイー | ヒトメタニューモウイルスワクチン |
| EP4380960A4 (en) * | 2021-08-05 | 2025-07-02 | Univ California | GLYCOMODIFIED FOLDON DOMAINS AND RELATED COMPOSITIONS AND METHODS |
| EP4448802A1 (en) * | 2021-12-16 | 2024-10-23 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| JP2026504862A (ja) | 2023-01-18 | 2026-02-10 | ファイザー・インク | 呼吸器疾患に対するワクチン |
| EP4661905A2 (en) * | 2023-02-06 | 2025-12-17 | Cyanvac LLC | Modified piv5 vaccine vectors: methods of making and uses |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025201243A1 (zh) * | 2024-03-25 | 2025-10-02 | 中国医学科学院医学生物学研究所 | 重组呼吸道合胞病毒融合前f蛋白突变体和其用途 |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| CN119176858B (zh) * | 2024-11-22 | 2026-01-09 | 北京华诺泰生物医药科技有限公司 | 一种重组人偏肺病毒融合前f蛋白纯化方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5547871A (en) | 1993-01-25 | 1996-08-20 | American Cyanamid Company | Heterologous signal sequences for secretion of insect controlling proteins |
| ATE509102T1 (de) | 1994-07-15 | 2011-05-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
| AT408721B (de) | 1999-10-01 | 2002-02-25 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung enthaltend ein antigen |
| AT409085B (de) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
| AU2001281812B2 (en) | 2000-06-08 | 2005-04-07 | Valneva Austria Gmbh | Immunostimulatory oligodeoxynucleotides |
| AT410173B (de) | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
| US20040170642A1 (en) | 2000-08-17 | 2004-09-02 | Jorg Fritiz | Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof |
| AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
| US8715922B2 (en) * | 2001-01-19 | 2014-05-06 | ViroNovative | Virus causing respiratory tract illness in susceptible mammals |
| JP4188092B2 (ja) | 2001-05-21 | 2008-11-26 | インターツェル・アクチェンゲゼルシャフト | 免疫促進性オリゴデオキシ核酸分子 |
| JP2005519035A (ja) | 2001-12-07 | 2005-06-30 | インターツェル・アクチェンゲゼルシャフト | 免疫促進性オリゴデオキシヌクレオチド |
| DE10221836A1 (de) * | 2002-05-16 | 2003-12-04 | Lohmann Animal Health Gmbh | Attenuierung von Metapneumovirus |
| ATE485056T1 (de) | 2003-03-24 | 2010-11-15 | Intercell Ag | Verbesserte impfstoffe |
| CN101410519B (zh) | 2003-04-25 | 2013-04-24 | 免疫医疗有限责任公司 | 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法 |
| AU2010264686A1 (en) | 2009-06-24 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Vaccine |
| US20120315270A1 (en) | 2009-10-21 | 2012-12-13 | The United States Of America, As Represented By The | Rsv immunogens, antibodies and compositions thereof |
| CN102145167A (zh) * | 2010-02-05 | 2011-08-10 | 重庆医科大学附属儿童医院 | 重组人类偏肺病毒疫苗 |
| AU2011258165B2 (en) | 2010-05-26 | 2016-11-17 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
| ES2647882T3 (es) | 2011-12-06 | 2017-12-27 | Valneva Austria Gmbh | Compuestos de aluminio para su uso en productos terapéuticos y vacunas |
| MY171210A (en) * | 2013-06-17 | 2019-10-02 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f polypeptides |
| CL2013002829A1 (es) | 2013-10-01 | 2014-04-04 | Univ Pontificia Catolica Chile | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv. |
| EP3236998A1 (en) * | 2014-12-24 | 2017-11-01 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Recombinant metapneumovirus f proteins and their use |
| CA2996762A1 (en) * | 2015-08-31 | 2017-03-09 | Technovax, Inc. | Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine |
| TW201729835A (zh) | 2015-10-22 | 2017-09-01 | 現代公司 | 呼吸道病毒疫苗 |
| EP3474893A1 (en) | 2016-06-27 | 2019-05-01 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens |
| WO2019092002A1 (en) * | 2017-11-07 | 2019-05-16 | Valneva Se | Pharmaceutical compositions for treatment or prevention of viral infections |
| PH12021552736A1 (en) | 2019-05-20 | 2022-07-11 | Valneva Se | A subunit vaccine for treatment or prevention of a respiratory tract infection |
| JP2024522385A (ja) | 2021-04-09 | 2024-06-19 | ヴァルネヴァ エスイー | ヒトメタニューモウイルスワクチン |
-
2020
- 2020-05-19 PH PH1/2021/552736A patent/PH12021552736A1/en unknown
- 2020-05-19 CN CN202080030901.9A patent/CN114127101A/zh active Pending
- 2020-05-19 MY MYPI2021005570A patent/MY208001A/en unknown
- 2020-05-19 AU AU2020277661A patent/AU2020277661A1/en active Pending
- 2020-05-19 GB GB2114836.6A patent/GB2598494B/en active Active
- 2020-05-19 US US17/606,811 patent/US12162907B2/en active Active
- 2020-05-19 KR KR1020217034461A patent/KR20220010478A/ko not_active Ceased
- 2020-05-19 EP EP20726137.1A patent/EP3972639A1/en active Pending
- 2020-05-19 MX MX2021013111A patent/MX2021013111A/es unknown
- 2020-05-19 SG SG11202110646PA patent/SG11202110646PA/en unknown
- 2020-05-19 PE PE2021001766A patent/PE20220400A1/es unknown
- 2020-05-19 WO PCT/EP2020/063973 patent/WO2020234300A1/en not_active Ceased
- 2020-05-19 CA CA3138064A patent/CA3138064A1/en active Pending
- 2020-05-19 BR BR112021021637A patent/BR112021021637A2/pt unknown
- 2020-05-19 JP JP2021564088A patent/JP2022533318A/ja active Pending
-
2021
- 2021-09-17 ZA ZA2021/06883A patent/ZA202106883B/en unknown
- 2021-10-07 IL IL287099A patent/IL287099A/en unknown
- 2021-10-25 EC ECSENADI202179178A patent/ECSP21079178A/es unknown
- 2021-10-26 CL CL2021002819A patent/CL2021002819A1/es unknown
- 2021-10-29 CO CONC2021/0014694A patent/CO2021014694A2/es unknown
- 2021-11-10 SA SA521430813A patent/SA521430813B1/ar unknown
-
2023
- 2023-10-24 US US18/493,004 patent/US12162909B2/en active Active
-
2024
- 2024-10-31 US US18/932,700 patent/US20250171501A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021002819A1 (es) | 2022-07-08 |
| PH12021552736A1 (en) | 2022-07-11 |
| KR20220010478A (ko) | 2022-01-25 |
| US20240067681A1 (en) | 2024-02-29 |
| MY208001A (en) | 2025-04-03 |
| IL287099A (en) | 2021-12-01 |
| JP2022533318A (ja) | 2022-07-22 |
| ZA202106883B (en) | 2022-07-27 |
| GB2598494A (en) | 2022-03-02 |
| AU2020277661A1 (en) | 2021-10-21 |
| US12162907B2 (en) | 2024-12-10 |
| CA3138064A1 (en) | 2020-11-26 |
| EP3972639A1 (en) | 2022-03-30 |
| PE20220400A1 (es) | 2022-03-22 |
| WO2020234300A1 (en) | 2020-11-26 |
| SA521430813B1 (ar) | 2024-04-27 |
| GB202114836D0 (en) | 2021-12-01 |
| ECSP21079178A (es) | 2021-11-30 |
| MX2021013111A (es) | 2021-11-17 |
| US20250171501A1 (en) | 2025-05-29 |
| US20220185847A1 (en) | 2022-06-16 |
| BR112021021637A2 (pt) | 2021-12-21 |
| CN114127101A (zh) | 2022-03-01 |
| GB2598494B (en) | 2024-07-24 |
| US12162909B2 (en) | 2024-12-10 |
| CO2021014694A2 (es) | 2022-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12162909B2 (en) | Subunit vaccine for treatment or prevention of a respiratory tract infection | |
| US12233124B2 (en) | Recombinant metapneumovirus f proteins and their use | |
| JP7094103B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| JP2023524054A (ja) | ベータコロナウイルスの予防と治療 | |
| US9060975B2 (en) | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions | |
| EP3532095A1 (en) | Prefusion coronavirus spike proteins and their use | |
| JP2018520159A (ja) | Ｒｓｖに対するワクチン | |
| US20240181034A1 (en) | Human metapneumo virus vaccine | |
| JP2021511077A (ja) | インフルエンザウイルスワクチン及びその使用 | |
| CN117202928A (zh) | 用于偏肺病毒的基于蛋白质的纳米颗粒疫苗 | |
| US20250222095A1 (en) | Respiratory syncytial virus recombinant fusion protein with pre-fusion conformation, preparation method and uses thereof | |
| JP2026506434A (ja) | ライノウイルスｍＲＮＡワクチン | |
| KR20240163165A (ko) | 에피토프의 조합과 그의 용도, 백신 구조물, 면역 반응의 유도 방법 에피토프의 식별 방법 | |
| RU2811991C2 (ru) | Субъединичная вакцина для лечения или предотвращения инфекции дыхательных путей | |
| US11723968B2 (en) | Stabilized recombinant hantaviral spike proteins comprising mutations in Gc | |
| KR20230105300A (ko) | 스캐폴드 기반의 다중항원을 포함하는 코로나바이러스 감염병 예방 또는 치료용 항원 조성물 | |
| CN119161495B (zh) | 呼吸道合胞病毒重构多肽及其应用 | |
| WO2020264011A1 (en) | Resurfaced dengue virus and ziki virus glycoprotein e diii variants and uses thereof | |
| HK40098178A (zh) | 人偏肺病毒疫苗 | |
| JP2020162607A (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| Jaberolansar | Epitope-focused vaccines against respiratory syncytial virus |